Introduction {#Sec1}
============

Hypoxia has been shown to exert immunomodulatory effects^1^. As oxygenation is daily practice in critical care, and the majority of critically ill patients suffer from inflammatory-related conditions, *permissive hypoxia* might be a novel therapeutic strategy. In addition, there are pharmacologic hypoxia-mimetics available that can replicate the hypoxia-effects without the potential drawbacks of systemic hypoxia. The hypoxic immunomodulatory effects are thought to be mediated through a group of transcription factors called hypoxia-inducible factors (HIFs)^2^. However, *in vitro* studies have demonstrated that, depending on the cell-type, these effects can be both pro- and anti-inflammatory. The net effects of hypoxia during systemic inflammation *in vivo* are therefore unknown.

Objectives {#Sec2}
==========

To determine the immunomodulatory effects of various degrees of hypoxia and hypoxia mimetics during systemic inflammation in mice.

Methods {#Sec3}
=======

BALB/c mice (n = 8 per group) were placed in an air-tight cage with variable degrees of oxygen (normal (21%), 12%, 9%, and 6%), or were injected with the hypoxia-mimetic cobalt chloride (CoCl~2,~ 30mg/kg i.p.). After 1 hour, LPS (5 mg/kg *E. Coli* endotoxin, serotype 0111:B4) or placebo (NaCl 0.9%) was administered i.p. Ninety minutes after LPS/placebo administration, rectal temperature was measured and animals were sacrificed. Blood plasma was analyzed for cytokine concentrations. Furthermore, mRNA expression of interleukin (IL)-10 and the HIF-1α target gene vascular endothelial growth factor (VEGF) were determined in spleen samples.

Results {#Sec4}
=======

As expected, LPS administration resulted in hypothermia. Hypoxia and CoCl~2~ also lowered body temperature, in a dose-dependent fashion (Figure [1](#Fig1){ref-type="fig"}). Hypoxia itself did not result in elevated cytokine levels in plasma. Endotoxemia resulted in increased levels of circulating pro-inflammatory cytokines Tumor Necrosis Factor (TNF)-α, IL-6, IL-8, as well as anti-inflammatory IL-10 (Figure [2](#Fig2){ref-type="fig"}). Hypoxia and CoCl~2~ attenuated the endotoxin-induced pro-inflammatory cytokine response in a dose-dependent manner, while IL-10 protein levels were relatively unaffected. Furthermore, hypoxia resulted in a dose-dependent upregulation of splenic VEGF and IL-10 mRNA expression (Figure [3](#Fig3){ref-type="fig"}).Figure 1**Rectal temperature in degrees Celsius (°C). Data are shown as mean ± SEM. Stastistical analysis was performed using two-way analysis of variance with Bonferonni post-hoc tests. \* p \< 0.05 compared with normoxia (21% with same LPS/placebo) \# p \< 0.05 compared with placebo (same % oxygen or CoCl2).**Figure 2**Plasma cytokines (Tumor Necrosis Factor (TNF)α, Interleukin(IL)-6, IL-8 and IL-10). Data are shown as mean ± SEM. Statistical analysis was performed using two-way analysis of variance with Bonferonni post-hoc tests. \* p \< 0.05 compared with normoxia (21% with same LPS/placebo). \# p \< 0.05 compared with placebo (same % oxygen of CoCl2)**Figure 3**Splenic mRNA expression of Interleukin 10 (IL-10) and vascular endothelial growth factor (VEGF). Data are shown as mean ± SEM. Statistical analysis was performed using two-way analysis of variance with Bonferonni post-hoc tests. \* p \< 0.05 compared with normoxia (21% with same LPS/placebo). \# p \< 0.05 compared with placebo (same % oxygen of CoCl2)**

Conclusions {#Sec5}
===========

Hypoxia results in hypothermia and attenuation of the systemic pro-inflammatory response in a dose-dependent fashion, while preserving or enhancing the anti-inflammatory response. Administration of the hypoxia-mimetic CoCl~2~ results in a similar immunological phenotype. Our results suggest that permissive hypoxia is a novel non-pharmacological anti-inflammatory therapeutic strategy.
